Type of medical product:

Protein based




Allergic diseases

Indications for use:

Bronchial asthma


R&D stage

The agent   is a recombinant humanized monoclonal antibody  for treatment of atopic bronchial asthma of moderate and severe course.

Bronchial asthma is a chronic inflammatory disease of respiratory system involving various cellular elements. Its key part is bronchial obstruction (bronchial lumen narrowing) due to specific immune (sensitization and allergy) or non-specific mechanisms manifested with recurrent episodes of wheezing, dyspnea, chest congestion and coughing.

Globally bronchial asthma incidence is 4 to 10% of population. In Russia the incidence rate among adults varies from 2.2 to 7%, as per different publications while in pediatric population it is about 10 %. The disease emerges in any age. About half of patients develop bronchial asthma before 10 years of age, another third — before 40. Since mid-1980's bronchial asthma incidence started to rise. Incidence growth is associated with environmental pollution and sedentary lifestyle.